SCHEMBL25418079

SCHEMBL25418079

CON(C)C(=O)c1coc(N2CCN(C(=O)OC(C)(C)C)CC2)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.41
▸ GPR119 Q8TDV5 6/20 0.40
▸ CKS1B P61024 2/20 0.40
▸ SKP1 P63208 2/20 0.40
▸ SKP2 Q13309 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MAP4K4 O95819 1/20 0.39
▸ ADORA2A P29274 1/20 0.38
▸ ADORA1 P30542 1/20 0.38
▸ F2RL3 Q96RI0 1/20 0.38
▸ USP2 O75604 1/20 0.37
▸ SUV39H2 Q9H5I1 2/20 0.37
▸ ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31197676 0.86 CKS1B (0.45) MAPTALDH1A1LMNATLR9GPR119
SCHEMBL17373792 0.83 CKS1B (0.46) MAPTALDH1A1LMNAGPR119CKS1B
SCHEMBL31197670 0.80 CKS1B (0.50) MAPTALDH1A1LMNAGPR119CKS1B
SCHEMBL25417327 0.79 GPR119 (0.44) MAPTALDH1A1LMNATLR9GPR119
SCHEMBL17373778 0.79 CKS1B (0.43) MAPTALDH1A1LMNAGPR119CKS1B
SCHEMBL14990872 0.78 CKS1B (0.46) MAPTALDH1A1LMNAGPR119CKS1B
SCHEMBL25419563 0.78 CKS1B (0.49) MAPTALDH1A1LMNAGPR119CKS1B
SCHEMBL23120623 0.76 CKS1B (0.50) MAPTALDH1A1LMNAGPR119CKS1B
SCHEMBL26094150 0.75 CKS1B (0.43) MAPTALDH1A1LMNATLR9GPR119
SCHEMBL31197679 0.75 CKS1B (0.46) MAPTALDH1A1LMNAGPR119CKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2025-04-24 — — US disclosed
EP-4430047-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2024-09-18 — — EP disclosed
CN-118475580-A Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof 普罗根托斯治疗公司 2024-08-09 — — CN disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 — — WO disclosed
WO-2023081923-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF Frequency Therapeutics, Inc. (US) 2023-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129067-A1 PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF PDGFRB, PDGFRA, PDGFA MAPT 2829/4885ALDH1A1 3250/4885LMNA 3890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback